Biosimilars for Retinal Diseases: An Update

To review the biosimilars of anti–vascular endothelial growth factor agents for retinal diseases and provide an update about their development. Literature review. A comprehensive literature review was performed for scientific articles, clinical trials, and press releases for the development of biosi...

Full description

Saved in:
Bibliographic Details
Published in:American journal of ophthalmology 2021-04, Vol.224, p.36-42
Main Authors: Sharma, Ashish, Kumar, Nilesh, Parachuri, Nikulaa, Bandello, Francesco, Kuppermann, Baruch D., Loewenstein, Anat
Format: Article
Language:English
Subjects:
Angiogenesis Inhibitors - chemistry
Angiogenesis Inhibitors - pharmacology
Angiogenesis Inhibitors - therapeutic use
Biological products
Biosimilar Pharmaceuticals - chemistry
Biosimilar Pharmaceuticals - pharmacology
Biosimilar Pharmaceuticals - therapeutic use
Clinical trials
Clinical Trials as Topic
Digital archives
Drug Approval
Drug Development
Expenditures
FDA approval
Humans
Letters
Manufacturers
Manufacturing
Marketing
Pharmacodynamics
Ranibizumab - chemistry
Ranibizumab - pharmacology
Ranibizumab - therapeutic use
Receptors, Vascular Endothelial Growth Factor - chemistry
Receptors, Vascular Endothelial Growth Factor - therapeutic use
Recombinant Fusion Proteins - chemistry
Recombinant Fusion Proteins - pharmacology
Recombinant Fusion Proteins - therapeutic use
Retinal Diseases - drug therapy
Vascular endothelial growth factor
Vascular Endothelial Growth Factor A - antagonists & inhibitors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To review the biosimilars of anti–vascular endothelial growth factor agents for retinal diseases and provide an update about their development. Literature review. A comprehensive literature review was performed for scientific articles, clinical trials, and press releases for the development of biosimilars in ophthalmology. To date, Razumab (Intas Pharmaceuticals Ltd, Ahmedabad, GJ, India) is the only approved biosimilar for ophthalmic use, but the landscape will rapidly change in the future with multiple biosimilar candidates, which are currently in phase 3 trials, showing promising early results. Biosimilars hold the potential to reduce the financial burden of the highly efficacious biologic therapy in retinal pathologies. However, the off-label bevacizumab may differentiate the success of biosimilars in different geographic regions.
ISSN:0002-9394
1879-1891
DOI:10.1016/j.ajo.2020.11.017